Abstract
Mood disorders represent one of society's most costly and challenging health burdens. The drug treatments used today were initially discovered serendipitously in the 1950s. Animal models were then developed based on the ability of these drugs to alter specific behaviours. These models have played a major role in the development of the second generation of antidepressants. However, their use has been heavily criticized, particularly in relation to whether they recapitulate similar underlying biology to the psychiatric disorder they are proposed to represent. This article considers our work in the field of affective bias and the development of a translational research programme to try to develop and validate better animal models. We discuss whether the new data that have arisen from these studies support an alternative perspective on the underlying neurobiological processes that lead to major depressive disorder (MDD). Specifically, this article will consider whether a neuropsychological mechanism involving affective biases plays a causal role in the development of MDD and its associated emotional and behavioural symptoms. These animal studies also raise the possibility that neuropsychological mechanisms involving affective biases are a precursor to, rather than a consequence of, the neurotrophic changes linked to MDD.This article is part of a discussion meeting issue ‘Of mice and mental health: facilitating dialogue between basic and clinical neuroscientists’.
Highlights
Affective disorders are the most prevalent mental health conditions affecting modern society, with major depressive disorders (MDD) expected to become the leading cause of disability adjust life years by 2020
MDD is a disease characterized by a broad range of symptoms that are largely defined based on subjective self-report measures (e.g. DSM-V [6])
In our consideration of affective biases, we have looked more widely at the deficits reported in MDD and used this evidence to inform our subsequent animal work
Summary
Affective disorders are the most prevalent mental health conditions affecting modern society, with major depressive disorders (MDD) expected to become the leading cause of disability adjust life years by 2020. The development of the serotonin specific re-uptake inhibitors provides an excellent example of this These drugs are the most widely used treatments for both anxiety and MDD and are often prescribed to other patient populations to try to address co-morbid mood symptoms. MDD is a disease characterized by a broad range of symptoms that are largely defined based on subjective self-report measures (e.g. DSM-V [6]) These criteria cannot be replicated directly in a pre-clinical scenario and as such, current animal models are assessed based on criteria such as face (resembles some characteristic of the human condition e.g. anhedonia, behavioural despair), construct (arises as a consequence of similar predisposing factors e.g. stress, genetic vulnerability, early life adversity) and predictive validity (the ability to predict in an animal the clinical effects of a treatment) [7,8,9]. This article summarizes progress to date and considers the possible implications of the findings that have arisen from our validation work and investigations into novel neurobiology
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Philosophical Transactions of the Royal Society B: Biological Sciences
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.